AI-Guided Cancer Vaccines Signal a New Era in Personalized Medicine
/in Artificial Intelligence, Immunotherapy, Preclinical Research/by MaxAI-Powered Drug Repurposing Advances: Using Artificial Intelligence to Find New Cancer Treatments
/in Artificial Intelligence/by MaxAI Strikes Again: FDA Cleared an AI That Outperformed Human Pathologists in Missed Cases
/in Artificial Intelligence/by MaxRepurposing Non-Cancer Drugs: A New Frontier in Personalized Oncology
/in Artificial Intelligence, Preclinical Research/by MaxGenomenon Unveils Groundbreaking Genomic Knowledgebase Powered by AI
/in Artificial Intelligence/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Final PEACE-3 Trial Data: Radium-223 + Enzalutamide Extends Survival by 5.6 Months in Bone mCRPC. March 2, 2026
- Phase 2 Trial of Cu-64 SAR-bisPSMA Doubles Prostate Lesion Detection March 2, 2026
- Newsletter 9/2026 March 1, 2026
- CT Muscle Measure Guides Treatment Benefit in New Prostate Cancer: STAMPEDE Findings February 25, 2026
